[go: up one dir, main page]

UY34166A - Composición farmacéutica oftalmológica tópica que contiene regorafenib - Google Patents

Composición farmacéutica oftalmológica tópica que contiene regorafenib

Info

Publication number
UY34166A
UY34166A UY0001034166A UY34166A UY34166A UY 34166 A UY34166 A UY 34166A UY 0001034166 A UY0001034166 A UY 0001034166A UY 34166 A UY34166 A UY 34166A UY 34166 A UY34166 A UY 34166A
Authority
UY
Uruguay
Prior art keywords
typical
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
containing regorafenib
Prior art date
Application number
UY0001034166A
Other languages
English (en)
Inventor
Boettger Dr Michael
Degenfeld Dr Georges
Freundlieb Dr Julia
Hirth-Dietrich Dr Claudia
Keldenich Dr Joerg
Klar Dr Juergen
Muenster Dr Uwe
Ohm Dr Andreas
Richter Dr Annett
Riedl Dr Bernd
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of UY34166A publication Critical patent/UY34166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas oftalmológicas tópicas que contienen regorafenib, un hidrato, solvato o sal farmacéuticamente aceptable del mismo o un polimorfo del mismo y su procedimiento de preparación y su uso para el tratamiento de trastornos oftalmológicos.
UY0001034166A 2011-06-28 2012-06-27 Composición farmacéutica oftalmológica tópica que contiene regorafenib UY34166A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14

Publications (1)

Publication Number Publication Date
UY34166A true UY34166A (es) 2013-01-31

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034166A UY34166A (es) 2011-06-28 2012-06-27 Composición farmacéutica oftalmológica tópica que contiene regorafenib

Country Status (26)

Country Link
US (1) US20140296301A1 (es)
EP (1) EP2726059A1 (es)
JP (1) JP5998213B2 (es)
KR (1) KR20140048218A (es)
CN (1) CN103889399A (es)
AP (1) AP2013007335A0 (es)
AR (1) AR086800A1 (es)
AU (1) AU2012277905A1 (es)
BR (1) BR112013033831A2 (es)
CA (1) CA2840329A1 (es)
CL (1) CL2013003700A1 (es)
CO (1) CO6920289A2 (es)
CR (1) CR20130693A (es)
CU (1) CU24163B1 (es)
DO (1) DOP2013000314A (es)
EA (1) EA201400064A1 (es)
EC (1) ECSP13013106A (es)
GT (1) GT201300322A (es)
HK (1) HK1197176A1 (es)
MX (1) MX2013015287A (es)
PE (1) PE20141031A1 (es)
PH (1) PH12013502691A1 (es)
TN (1) TN2013000533A1 (es)
UY (1) UY34166A (es)
WO (1) WO2013000917A1 (es)
ZA (1) ZA201400646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553804A (en) 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
ES2693094T3 (es) * 2002-05-28 2018-12-07 Astrazeneca Ab Preparación farmacéutica de aplicación tópica
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
ATE428401T1 (de) 2005-05-10 2009-05-15 Alcon Inc Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
WO2006133411A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US20080293691A1 (en) 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
JP2009519267A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
ATE535243T1 (de) * 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
KR20120049267A (ko) 2009-07-16 2012-05-16 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 치료 방법

Also Published As

Publication number Publication date
CA2840329A1 (en) 2013-01-03
CU24163B1 (es) 2016-03-31
AU2012277905A1 (en) 2014-01-16
BR112013033831A2 (pt) 2017-02-14
CL2013003700A1 (es) 2014-07-18
CN103889399A (zh) 2014-06-25
AR086800A1 (es) 2014-01-22
JP2014518233A (ja) 2014-07-28
CO6920289A2 (es) 2014-04-10
CR20130693A (es) 2016-05-02
US20140296301A1 (en) 2014-10-02
NZ619229A (en) 2016-04-29
ECSP13013106A (es) 2014-01-31
MX2013015287A (es) 2014-03-31
AP2013007335A0 (en) 2013-12-31
KR20140048218A (ko) 2014-04-23
GT201300322A (es) 2014-11-13
EA201400064A1 (ru) 2014-05-30
AU2012277905A8 (en) 2014-01-30
JP5998213B2 (ja) 2016-09-28
TN2013000533A1 (en) 2015-03-30
CU20130168A7 (es) 2014-04-24
PH12013502691A1 (en) 2017-08-23
HK1197176A1 (en) 2015-01-09
PE20141031A1 (es) 2014-08-21
DOP2013000314A (es) 2014-04-15
ZA201400646B (en) 2015-11-25
WO2013000917A1 (en) 2013-01-03
EP2726059A1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
JOP20180103A1 (ar) مركب صيدلاني
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
UY34414A (es) Composiciones hemostáticas
ECSP13013074A (es) Nuevos derivados de piridina
UY34365A (es) Compuestos heterociclicos
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
UY34550A (es) Bencilpirazoles sustituidos
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
ECSP14013169A (es) Tableta a prueba de alteración que proporciona liberación inmediata del fármaco
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY33930A (es) Inhibidores novedosos de quinasas
CR20150204A (es) Nuevos derivados de piridina
UY34415A (es) Composiciones hemostáticas
BR112015012907A2 (pt) composição de cuidado pessoal
UY34800A (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos
UY34158A (es) Composicion herbicida
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020